public
larg
kept
uninform
basi
understand
trust
establish
next
month
becom
extrem
import
govern
regulatori
author
initi
open
public
debat
deliber
releas
order
provid
balanc
inform
without
open
debat
polar
unwork
entrench
develop
biotechnolog
industri
oppon
europ
multimedia
programm
partli
financ
european
commiss
start
provid
public
inform
mani
posit
contribut
new
genet
technolog
could
make
like
crop
diseas
insect
resist
higher
nutrit
valu
stake
mistak
born
concern
share
price
scientif
prestig
tri
sell
public
wonder
biotechnolog
without
properli
address
risk
public
suspicion
delay
develop
iceminu
case
clearli
demonstr
hard
us
imagin
revolutionari
discoveri
first
descript
substanc
alec
isaac
call
interferon
late
mani
figment
vivid
scientif
imagin
yet
origin
observ
care
repeat
mani
laboratori
product
cell
solubl
substanc
explain
viral
interfer
less
accept
interferon
discov
realiz
possibl
interfer
viral
replic
without
necessarili
endang
cellular
metabol
mani
thought
interferon
might
prove
use
antivir
agent
howev
major
problem
materi
suppli
remain
clone
interferon
gene
ine
coliin
late
concomit
success
develop
largescal
lymphoblastoid
interferon
product
give
exampl
earli
suppli
problem
twoyear
collabor
glaxo
wellcom
laboratori
produc
suffici
monkey
kidney
cell
interferon
singl
small
dose
inocul
intraderm
volunt
prevent
vaccinia
expens
busi
even
though
trial
success
vaccinia
appear
highli
suscept
rive
consid
dubiou
commerci
merit
kari
cantel
start
make
leucocyt
interferon
buffi
coat
blood
destin
transfus
manag
make
suffici
suppli
nearli
import
trial
report
success
trial
report
ref
repeat
intrans
spray
interferon
experiment
common
cold
volunt
given
rhinoviru
type
use
one
year
manufactur
suppli
process
thu
although
success
insuffici
interferon
pursu
studi
let
alon
sell
interferon
common
cold
greenberg
cowork
establish
minimum
dose
interferon
could
protect
volunt
rhinoviru
devis
way
enhanc
effect
exampl
put
cotton
wool
pledget
satur
interferon
nose
use
concomit
partli
excit
result
viral
studi
perhap
unreason
predict
interferon
would
power
effect
human
tumour
dna
chemist
address
problem
clone
express
human
interferon
gene
done
remark
success
sever
pharmaceut
compani
collabor
gene
technolog
firm
develop
product
work
understood
even
though
success
trial
done
buffi
coat
interferon
product
gene
clone
need
thoroughli
evalu
qualiti
assur
activ
toxic
much
way
new
pharmaceut
product
mani
ainterferon
gene
far
evid
one
interferon
better
anoth
develop
al
predomin
natur
leucocyt
lymphoblastoid
prepar
clone
yinterferon
also
trial
result
slow
emerg
surpris
progress
seem
slow
much
artifici
enthusiasm
cureal
product
wane
sinc
hope
predict
made
public
time
quit
unrealist
gener
felt
work
interferon
field
nevertheless
interferon
appear
import
clinic
applic
common
cold
pursu
dilig
sever
group
find
mani
trial
summar
recent
phillpott
tyrrel
show
first
interferon
given
viru
prevent
cold
surpris
consid
maxim
endogen
interferon
respons
coincid
peak
viru
replic
turn
coincid
symptom
secondli
minimum
dose
need
inhibit
viru
given
time
day
night
intranas
taken
sort
dose
schedul
offer
protect
experiment
coronaviru
influenza
viru
infect
although
sever
studi
shown
excel
protect
rhinoviru
interferon
given
day
intranas
interferon
continu
day
volunt
begin
develop
local
nasal
symptom
reflect
nasal
mucos
ulcer
intens
mucos
lymphocyt
infiltr
sideeffect
seem
consist
interferon
test
dose
depend
may
made
wors
preserv
nasal
solut
end
two
week
mani
volunt
take
minimum
dose
need
protect
wild
cold
may
symptom
two
recent
paper
publish
group
usa
australia
attempt
prevent
natur
cold
famili
contact
use
short
welltoler
cours
intranas
interferon
intron
schere
corpor
similar
protocol
use
result
almost
ident
studi
possibl
way
common
cold
virus
appear
transmit
reservoir
circul
virus
mainli
nonimmun
children
school
play
close
contact
observ
simpl
hygien
precaut
children
contract
cold
bring
home
larg
quantiti
viru
nasal
secret
infect
suscept
adult
princip
mucosatohandtomucosa
contact
even
via
fomit
contamin
nasal
mucu
mani
respiratori
virus
surviv
hour
trial
one
famili
member
develop
symptom
cold
treatment
intranas
interferon
placebo
start
famili
member
except
children
compar
placebo
recipi
interferon
recipi
significantli
fewer
rhinoviru
cold
fewer
infect
caus
corona
influenza
pareinfluenza
virus
howev
cold
interferon
recipi
less
sever
clear
benefici
effect
intranas
interferon
natur
acquir
cold
perhap
better
effect
virus
could
achiev
increas
frequenc
dose
trial
new
dose
schedul
difficult
expens
interferon
use
way
avail
cheapli
counter
taken
soon
enough
effect
perhap
initi
could
use
cold
inconveni
nuisanc
may
exampl
herald
worsen
bronchiti
asthma
diabet
clone
new
protein
e
coil
yeast
gener
new
magic
immun
modul
vaccin
bound
alter
cours
human
diseas
think
moment
time
financi
intellectu
invest
requir
bring
wonder
drug
profit
market
look
hard
long
develop
present
result
interferon
confus
clinician
heterogen
toxic
properti
enorm
potenti
spectrum
activ
